首頁 > 市場調查報告書 > 製藥

自體免疫疾病

市場調查報告書

商品編碼

2149069

免疫調節劑市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測。

Immunomodulators Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034

出版日期: 2026年10月01日 | 出版商:

Fortune Business Insights Pvt. Ltd. | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

免疫調節藥物市場的成長要素

全球免疫調節藥物市場預計到2025年將達到2506.9億美元，從2026年的2691.5億美元成長到2034年的4750.4億美元，2026年至2034年的複合年成長率為7.36%。北美在2025年將以38.32%的市佔率引領全球市場，這得益於自體免疫、活躍的藥物研究、臨床開發和新產品上市。

免疫調節劑是一類透過抑製或刺激免疫反應來調節免疫系統活性的藥物。免疫抑制劑廣泛用於預防自體免疫疾病和器官移植後的排斥反應，而免疫促效劑則包括疫苗、抗體和其他增強免疫反應的療法。對多發性硬化症、類風濕性關節炎、克隆氏症、癌症、呼吸系統疾病和其他疾病的研究不斷深入，推動了先進免疫調節療法的需求。

市場定義和範圍

免疫調節藥物市場涵蓋調節免疫系統功能的藥物。該市場大致分為免疫抑制劑和免疫促效劑，其應用領域包括腫瘤、呼吸系統疾病、愛滋病、自體免疫疾病、器官移植等。該市場還包括由製藥公司、生技公司、醫療機構及相關醫療管道開發和供應的產品。

市場動態

促進因素

自體免疫疾病盛行率的不斷上升是市場成長的主要驅動力。多發性硬化症、類風濕性關節炎、紅斑性狼瘡和克隆氏症疾病對能夠調節異常免疫反應的療法產生了顯著需求。臨床試驗的擴展和新型免疫療法的研發也促進了產品平臺的成長。

強大的藥物研發管線帶來了更多成長機會。製藥和生技公司正投資於聯合治療、生物製藥、標靶治療和新型免疫調節劑，以滿足尚未滿足的醫療需求。癌症免疫療法研究的活性化也擴大了免疫調節劑的潛在應用範圍。

趨勢

積極的研發投入是該市場的關鍵趨勢。各公司日益關注免疫療法、標靶藥物療法、單株抗體以及癌症和自體免疫疾病的先進療法。策略聯盟和夥伴關係正在幫助企業加速臨床開發和商業化進程。

阻礙因素

免疫調節藥物的副作用可能會阻礙市場擴張。免疫抑制療法可能會增加感染疾病和其他併發症的風險，某些療法也會引起疲勞、胃腸道問題、皮膚疾病和其他副作用。此外，臨床試驗和產品核可的嚴格監管要求也會增加研發時間和成本。

新冠疫情的影響

新冠疫情對免疫調節藥物市場產生了多項正面影響，包括藥品需求增加和對免疫療法的興趣高漲。製藥公司加強了供應鏈管理、生產能力、品管和研發活動，以確保產品供應。疫情也加速了免疫調節方法和潛在輔助療法的研究。

主要發現與總結
市場分析、洞察與預測：按產品類型分類
- 免疫抑制劑
- 免疫促效劑
市場分析、洞察與預測：按應用領域分類
- 呼吸系統
- 腫瘤學
- 多發性硬化症
- 其他
市場分析、洞察與預測：按地區分類
- 北美洲
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東和非洲

第6章：北美免疫調節劑市場分析、洞察與預測（2021-2034年）

國家
- 美國
- 加拿大

第7章：歐洲免疫調節劑市場分析、洞察與預測（2021-2034年）

國家
- 英國
- 德國
- 法國
- 西班牙
- 義大利
- 斯堪地那維亞
- 其他歐洲國家

第8章：亞太地區免疫調節劑市場分析、洞察與預測（2021-2034年）

國家
- 日本
- 中國
- 印度
- 澳洲
- 東南亞
- 其他亞太國家

第9章：拉丁美洲免疫調節劑市場分析、洞察與預測（2021-2034年）

國家
- 巴西
- 墨西哥
- 其他拉丁美洲國家

第10章：2021-2034年中東和非洲免疫調節劑市場分析、洞察與預測

國家
- GCC
- 南非
- 其他中東和非洲國家

第11章競爭分析

主要行業趨勢
全球市佔率分析（2025 年）
公司簡介
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Biogen
- Teva Pharmaceutical Industries Ltd.
- Amgen, Inc
- Bristol-Myers & Squibb Company
- Merck Sharp & Dohme Corp.
- Eli Lilly and Company
- Other Prominent Players

第12章戰略建議

簡介目錄圖表

Product Code: FBI104692

Growth Factors of immunomodulators Market

The global immunomodulators market size was valued at USD 250.69 billion in 2025 and is projected to grow from USD 269.15 billion in 2026 to USD 475.04 billion by 2034, registering a CAGR of 7.36% during 2026-2034. North America dominated the global market with a 38.32% share in 2025, supported by the high prevalence of autoimmune and chronic diseases, strong pharmaceutical research, clinical development, and product launches.

Immunomodulators are medicines that regulate immune-system activity by either suppressing or stimulating immune responses. Immunosuppressants are widely used for autoimmune disorders and to prevent organ rejection following transplantation, while immunostimulants include vaccines, antibodies, and other therapies that enhance immune responses. Increasing research into multiple sclerosis, rheumatoid arthritis, Crohn's disease, cancer, respiratory disorders, and other conditions is supporting demand for advanced immunomodulatory therapies.

Market Definition and Scope

The immunomodulators market covers pharmaceutical products that modify immune-system activity. The market is broadly classified into immunosuppressants and immunostimulants, with applications across oncology, respiratory diseases, HIV, autoimmune disorders, transplantation, and other medical conditions. The market also includes products developed and supplied through pharmaceutical and biotechnology companies, healthcare facilities, and related healthcare channels.

Market Dynamics

Drivers

The increasing prevalence of autoimmune diseases is a major factor driving market growth. Conditions such as multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease create significant demand for therapies that can regulate abnormal immune responses. Expanding clinical trials and the development of new immunotherapeutic agents are also contributing to the growing product pipeline.

The strong drug pipeline provides additional growth opportunities. Pharmaceutical and biotechnology companies are investing in combination therapies, biologics, targeted treatments, and novel immunomodulators to address unmet medical needs. Increasing research into cancer immunotherapy is also broadening the potential applications of immune-modulating medicines.

Trends

Robust research and development is a major trend in the market. Companies are increasingly focusing on immunotherapy, targeted drug therapy, monoclonal antibodies, and advanced treatments for cancer and autoimmune disorders. Strategic collaborations and partnerships are helping companies accelerate clinical development and commercialization.

Restraints

Adverse effects associated with immunomodulatory drugs can restrict market expansion. Immunosuppressive therapies may increase the risk of infections and other complications, while some treatments can cause fatigue, gastrointestinal problems, skin disorders, and other side effects. In addition, stringent regulatory requirements for clinical studies and product approvals can increase development timelines and costs.

Impact of COVID-19

The COVID-19 pandemic had a positive impact on the immunomodulators market in several areas because of increased demand for medicines and greater attention toward immune-related treatments. Pharmaceutical companies strengthened supply-chain management, manufacturing capabilities, quality control, and research activities to maintain product availability. The pandemic also encouraged research into immune-modulating approaches and potential supportive therapies.

Segmentation Analysis

By Product Type

The market is segmented into immunosuppressants and immunostimulants. Immunosuppressants held the largest market share, supported by their broad use in autoimmune diseases and transplantation. The immunostimulants segment is expected to witness strong growth as demand increases for vaccines, antibodies, and therapies designed to enhance immune responses.

By Application

Applications include oncology, respiratory, HIV, and others, with the other category covering conditions such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease. The respiratory segment is expected to account for a 37.9% share in 2025, while increasing cancer prevalence and growing adoption of immunotherapy are supporting the oncology segment.

Regional Insights

North America

North America generated USD 61.91 billion in 2025 and accounted for a 38.32% market share. High disease prevalence, strong pharmaceutical infrastructure, clinical research, and the presence of major market players support the region's leading position. The U.S. represents the largest contributor within the region.

Europe

Europe is an important market supported by pharmaceutical R&D investments and increasing sales of immunosuppressant drugs. The region is projected to grow at a CAGR of 6.2% during the forecast period.

Asia Pacific

Asia Pacific is projected to record strong growth, supported by increasing clinical studies, expanding healthcare infrastructure, and a growing geriatric population. China is projected to register a CAGR of 7.00%, while the immunomodulators market in Japan is expected to reach USD 7.70 billion in 2025.

Middle East & Africa and Latin America

These regions are expected to experience comparatively slower growth due to lower adoption of expensive therapies, limited healthcare infrastructure, and fewer product approvals in some developing countries.

Competitive Landscape

Major companies operating in the immunomodulators market include F. Hoffmann-La Roche Ltd., Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., and Eli Lilly and Company. Companies are focusing on R&D, strategic acquisitions, product launches, clinical development, and regulatory approvals to expand their portfolios.

Report Coverage

The immunomodulators market report covers market size and forecast, product types, applications, regional markets, leading companies, market trends, growth drivers, restraints, competitive developments, and industry opportunities. It also evaluates the impact of clinical research, drug pipelines, regulatory factors, and increasing demand for advanced immune-modulating therapies.

Conclusion

The global immunomodulators market is expected to expand from USD 250.69 billion in 2025 to USD 269.15 billion in 2026 and reach USD 475.04 billion by 2034, at a CAGR of 7.36%. Rising autoimmune and chronic disease prevalence, expanding clinical research, strong drug pipelines, and increasing applications in oncology and respiratory diseases are supporting market development. North America remains the leading regional market, while Asia Pacific is expected to experience strong growth during the forecast period.

Unit Value (USD Billion)

Segmentation Product Type; Application; and Region

By Product Type

Immunosuppressants
Immunostimulants

By Application

Respiratory
Oncology Multiple Sclerosis
Others

By Geography

North America
- By Product Type
- By Application
- By Country
USA (By Product Type)
Canada (By Product Type)
Europe
- By Product Type
- By Application
- By Country
UK (By Product Type)
Germany (By Product Type)
France (By Product Type)
Italy (By Product Type)
Spain (By Product Type)
Scandinavia (By Product Type)
Rest of Europe (By Product Type)
Asia Pacific
- By Product Type
- By Application
- By Country
Japan (By Product Type)
China (By Product Type)
Australia (By Product Type)
India (By Product Type)
Southeast Asia (By Product Type)
Rest of Asia Pacific (By Product Type)
Latin America
- By Product Type
- By Application
- By Country
Brazil (By Product Type)
Mexico (By Product Type)
Rest of Latin America (By Product Type)
The Middle East & Africa
- By Product Type
- By Application
- By Country
GCC (By Product Type)
South Africa (By Product Type)
Rest of Middle East & Africa (By Product Type)

Table of Content

1. Introduction

1.1. Market Scope
1.2. Market Segmentation
1.3. Market Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities

4. Key Insights

4.1. Prevalence of Key Disease Conditions -Key Regions/Country
4.2. New Product Launch
4.3. Pipeline Analysis
4.4. Impact of COVID-19 on the Immunomodulators Market
4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships

5. Global Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast - By Product Type
- 5.2.1. Immunosuppressants
- 5.2.2. Immunostimulants
5.3. Market Analysis, Insights and Forecast - By Application
- 5.3.1. Respiratory
- 5.3.2. Oncology
- 5.3.3. Multiple Sclerosis
- 5.3.4. Others
5.4. Market Analysis, Insights and Forecast - By Geography
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa

6. North America Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast - By Product Type
- 6.2.1. Immunosuppressants
- 6.2.2. Immunostimulants
6.3. Market Analysis, Insights and Forecast - By Application
- 6.3.1. Respiratory
- 6.3.2. Oncology
- 6.3.3. Multiple Sclerosis
- 6.3.4. Others
6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
  - 6.4.1.1. By Product Type
    - 6.4.1.1.1. Immunosuppressants
    - 6.4.1.1.2. Immunostimulants
- 6.4.2. Canada
  - 6.4.2.1. By Product Type
    - 6.4.2.1.1. Immunosuppressants
    - 6.4.2.1.2. Immunostimulants

7. Europe Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

7.1. Key Findings / Summary
7.2. Market Analysis, Insights and Forecast - By Product Type
- 7.2.1. Immunosuppressants
- 7.2.2. Immunostimulants
7.3. Market Analysis, Insights and Forecast - By Application
- 7.3.1. Respiratory
- 7.3.2. Oncology
- 7.3.3. Multiple Sclerosis
- 7.3.4. Others
7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.4.1. U.K.
  - 7.4.1.1. By Product Type
    - 7.4.1.1.1. Immunosuppressants
    - 7.4.1.1.2. Immunostimulants
- 7.4.2. Germany
  - 7.4.2.1. By Product Type
    - 7.4.2.1.1. Immunosuppressants
    - 7.4.2.1.2. Immunostimulants
- 7.4.3. France
  - 7.4.3.1. By Product Type
    - 7.4.3.1.1. Immunosuppressants
    - 7.4.3.1.2. Immunostimulants
- 7.4.4. Spain
  - 7.4.4.1. By Product Type
    - 7.4.4.1.1. Immunosuppressants
    - 7.4.4.1.2. Immunostimulants
- 7.4.5. Italy
  - 7.4.5.1. By Product Type
    - 7.4.5.1.1. Immunosuppressants
    - 7.4.5.1.2. Immunostimulants
- 7.4.6. Scandinavia
  - 7.4.6.1. By Product Type
    - 7.4.6.1.1. Immunosuppressants
    - 7.4.6.1.2. Immunostimulants
- 7.4.7. Rest of Europe
  - 7.4.7.1. By Product Type
    - 7.4.7.1.1. Immunosuppressants
    - 7.4.7.1.2. Immunostimulants

8. Asia Pacific Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

8.1. Key Findings / Summary
8.2. Market Analysis, Insights and Forecast - By Product Type
- 8.2.1. Immunosuppressants
- 8.2.2. Immunostimulants
8.3. Market Analysis, Insights and Forecast - By Application
- 8.3.1. Respiratory
- 8.3.2. Oncology
- 8.3.3. Multiple Sclerosis
- 8.3.4. Others
8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.4.1. Japan
  - 8.4.1.1. By Product Type
    - 8.4.1.1.1. Immunosuppressants
    - 8.4.1.1.2. Immunostimulants
- 8.4.2. China
  - 8.4.2.1. By Product Type
    - 8.4.2.1.1. Immunosuppressants
    - 8.4.2.1.2. Immunostimulants
- 8.4.3. India
  - 8.4.3.1. By Product Type
    - 8.4.3.1.1. Immunosuppressants
    - 8.4.3.1.2. Immunostimulants
- 8.4.4. Australia
  - 8.4.4.1. By Product Type
    - 8.4.4.1.1. Immunosuppressants
    - 8.4.4.1.2. Immunostimulants
- 8.4.5. Southeast Asia
  - 8.4.5.1. By Product Type
    - 8.4.5.1.1. Immunosuppressants
    - 8.4.5.1.2. Immunostimulants
- 8.4.6. Rest of Asia Pacific
  - 8.4.6.1. By Product Type
    - 8.4.6.1.1. Immunosuppressants
    - 8.4.6.1.2. Immunostimulants

9. Latin America Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

9.1. Key Findings / Summary
9.2. Market Analysis, Insights and Forecast - By Product Type
- 9.2.1. Immunosuppressants
- 9.2.2. Immunostimulants
9.3. Market Analysis, Insights and Forecast - By Application
- 9.3.1. Respiratory
- 9.3.2. Oncology
- 9.3.3. Multiple Sclerosis
- 9.3.4. Others
9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.4.1. Brazil
  - 9.4.1.1. By Product Type
    - 9.4.1.1.1. Immunosuppressants
    - 9.4.1.1.2. Immunostimulants
- 9.4.2. Mexico
  - 9.4.2.1. By Product Type
    - 9.4.2.1.1. Immunosuppressants
    - 9.4.2.1.2. Immunostimulants
- 9.4.3. Rest of Latin America
  - 9.4.3.1. By Product Type
    - 9.4.3.1.1. Immunosuppressants
    - 9.4.3.1.2. Immunostimulants

10. Middle East & Africa Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

10.1. Key Findings / Summary
10.2. Market Analysis, Insights and Forecast - By Product Type
- 10.2.1. Immunosuppressants
- 10.2.2. Immunostimulants
10.3. Market Analysis, Insights and Forecast - By Application
- 10.3.1. Respiratory
- 10.3.2. Oncology
- 10.3.3. Multiple Sclerosis
- 10.3.4. Others
10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.4.1. GCC
  - 10.4.1.1. By Product Type
    - 10.4.1.1.1. Immunosuppressants
    - 10.4.1.1.2. Immunostimulants
- 10.4.2. South Africa
  - 10.4.2.1. By Product Type
    - 10.4.2.1.1. Immunosuppressants
    - 10.4.2.1.2. Immunostimulants
- 10.4.3. Rest of Middle East & Africa
  - 10.4.3.1. By Product Type
    - 10.4.3.1.1. Immunosuppressants
    - 10.4.3.1.2. Immunostimulants

11. Competitive Analysis

11.1. Key Industry Developments
11.2. Global Market Share Analysis (2025)
11.3. Company Profiles
- 11.3.1. F. Hoffmann-La Roche Ltd
  - 11.3.1.1. Overview,
  - 11.3.1.2. Product Types & Services,
  - 11.3.1.3. SWOT Analysis,
  - 11.3.1.4. Recent Developments,
  - 11.3.1.5. Strategies,
  - 11.3.1.6. Financials (Based on Availability)
- 11.3.2. Novartis AG
  - 11.3.2.1. Overview,
  - 11.3.2.2. Product Types & Services,
  - 11.3.2.3. SWOT Analysis,
  - 11.3.2.4. Recent Developments,
  - 11.3.2.5. Strategies,
  - 11.3.2.6. Financials (Based on Availability)
- 11.3.3. Biogen
  - 11.3.3.1. Overview,
  - 11.3.3.2. Product Types & Services,
  - 11.3.3.3. SWOT Analysis,
  - 11.3.3.4. Recent Developments,
  - 11.3.3.5. Strategies,
  - 11.3.3.6. Financials (Based on Availability)
- 11.3.4. Teva Pharmaceutical Industries Ltd.
  - 11.3.4.1. Overview,
  - 11.3.4.2. Product Types & Services,
  - 11.3.4.3. SWOT Analysis,
  - 11.3.4.4. Recent Developments,
  - 11.3.4.5. Strategies,
  - 11.3.4.6. Financials (Based on Availability)
- 11.3.5. Amgen, Inc
  - 11.3.5.1. Overview,
  - 11.3.5.2. Product Types & Services,
  - 11.3.5.3. SWOT Analysis,
  - 11.3.5.4. Recent Developments,
  - 11.3.5.5. Strategies,
  - 11.3.5.6. Financials (Based on Availability)
- 11.3.6. Bristol-Myers & Squibb Company
  - 11.3.6.1. Overview,
  - 11.3.6.2. Product Types & Services,
  - 11.3.6.3. SWOT Analysis,
  - 11.3.6.4. Recent Developments,
  - 11.3.6.5. Strategies,
  - 11.3.6.6. Financials (Based on Availability)
- 11.3.7. Merck Sharp & Dohme Corp.
  - 11.3.7.1. Overview,
  - 11.3.7.2. Product Types & Services,
  - 11.3.7.3. SWOT Analysis,
  - 11.3.7.4. Recent Developments,
  - 11.3.7.5. Strategies,
  - 11.3.7.6. Financials (Based on Availability)
- 11.3.8. Eli Lilly and Company
  - 11.3.8.1. Overview,
  - 11.3.8.2. Product Types & Services,
  - 11.3.8.3. SWOT Analysis,
  - 11.3.8.4. Recent Developments,
  - 11.3.8.5. Strategies,
  - 11.3.8.6. Financials (Based on Availability)
- 11.3.9. Other Prominent Players
  - 11.3.9.1. Overview,
  - 11.3.9.2. Product Types & Services,
  - 11.3.9.3. SWOT Analysis,
  - 11.3.9.4. Recent Developments,
  - 11.3.9.5. Strategies,
  - 11.3.9.6. Financials (Based on Availability)

12. Strategic Recommendations

簡介目錄圖表

List of Tables

Table 1: Global Immunomodulators Market Revenue (USD billion) Forecast, by Region, 2021-2034
Table 2: Global Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
Table 3: Global Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 4: North America Immunomodulators Market Revenue (USD billion) Forecast, by Country, 2021-2034
Table 5: North America Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
Table 6: North America Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 7: Europe Immunomodulators Market Revenue (USD billion) Forecast, by Country, 2021-2034
Table 8: Europe Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
Table 9: Europe Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 10: Asia Pacific Immunomodulators Market Revenue (USD billion) Forecast, by Country, 2021-2034
Table 11: Asia Pacific Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
Table 12: Asia Pacific Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 13: Latin America Immunomodulators Market Revenue (USD billion) Forecast, by Country, 2021-2034
Table 14: Latin America Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
Table 15: Latin America Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 16: Middle East & Africa Immunomodulators Market Revenue (USD billion) Forecast, by Country, 2021-2034
Table 17: Middle East & Africa Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
Table 18: Middle East & Africa Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034

List of Figures

Figure 01: Global Immunomodulators Market Value Share (%), by Region, 2025 & 2034
Figure 02: Global Immunomodulators Market Value Share (%), By Product Type, 2025 & 2034
Figure 03: Global Immunomodulators Market Forecast (USD billion), By Immunosuppressants, 2025 -2034
Figure 04: Global Immunomodulators Market Forecast (USD billion), By Immunostimulants, 2025 -2034
Figure 05: Global Immunomodulators Market Value Share (%), By Application, 2025 & 2034
Figure 06: Global Immunomodulators Market Forecast (USD billion), By Respiratory, 2025 -2034
Figure 07: Global Immunomodulators Market Forecast (USD billion), By Oncology, 2025 -2034
Figure 08: Global Immunomodulators Market Forecast (USD billion), By Multiple Sclerosis, 2025 -2034
Figure 09: Global Immunomodulators Market Forecast (USD billion), By Others, 2025 -2034
Figure 10: North America Immunomodulators Market Value (USD billion), By Country, 2025 & 2034
Figure 11: North America Immunomodulators Market Value Share (%), By Country, 2025
Figure 12: North America Immunomodulators Market Value (USD billion), By Product Type, 2025 & 2034
Figure 13: North America Immunomodulators Market Value Share (%), By Product Type, 2025
Figure 14: North America Immunomodulators Market Value (USD billion), By Application, 2025 & 2034
Figure 15: North America Immunomodulators Market Value Share (%), By Application, 2025
Figure 16: Europe Immunomodulators Market Value (USD billion), By Country, 2025 & 2034
Figure 17: Europe Immunomodulators Market Value Share (%), By Country, 2025
Figure 18: Europe Immunomodulators Market Value (USD billion), By Product Type, 2025 & 2034
Figure 19: Europe Immunomodulators Market Value Share (%), By Product Type, 2025
Figure 20: Europe Immunomodulators Market Value (USD billion), By Application, 2025 & 2034
Figure 21: Europe Immunomodulators Market Value Share (%), By Application, 2025
Figure 22: Asia Pacific Immunomodulators Market Value (USD billion), By Country, 2025 & 2034
Figure 23: Asia Pacific Immunomodulators Market Value Share (%), By Country, 2025
Figure 24: Asia Pacific Immunomodulators Market Value (USD billion), By Product Type, 2025 & 2034
Figure 25: Asia Pacific Immunomodulators Market Value Share (%), By Product Type, 2025
Figure 26: Asia Pacific Immunomodulators Market Value (USD billion), By Application, 2025 & 2034
Figure 27: Asia Pacific Immunomodulators Market Value Share (%), By Application, 2025
Figure 28: Latin America Immunomodulators Market Value (USD billion), By Country, 2025 & 2034
Figure 29: Latin America Immunomodulators Market Value Share (%), By Country, 2025
Figure 30: Latin America Immunomodulators Market Value (USD billion), By Product Type, 2025 & 2034
Figure 31: Latin America Immunomodulators Market Value Share (%), By Product Type, 2025
Figure 32: Latin America Immunomodulators Market Value (USD billion), By Application, 2025 & 2034
Figure 33: Latin America Immunomodulators Market Value Share (%), By Application, 2025
Figure 34: Middle East & Africa Immunomodulators Market Value (USD billion), By Country, 2025 & 2034
Figure 35: Middle East & Africa Immunomodulators Market Value Share (%), By Country, 2025
Figure 36: Middle East & Africa Immunomodulators Market Value (USD billion), By Product Type, 2025 & 2034
Figure 37: Middle East & Africa Immunomodulators Market Value Share (%), By Product Type, 2025
Figure 38: Middle East & Africa Immunomodulators Market Value (USD billion), By Application, 2025 & 2034
Figure 39: Middle East & Africa Immunomodulators Market Value Share (%), By Application, 2025
Figure 40: Global Immunomodulators Market Revenue (%) Share Analysis by Key Players, 2025